ASCO COVID-19 Registry: Acceptable Registry for MIPS Improvement Activity

May 1, 2020

The Centers for Medicare & Medicaid Services (CMS) has confirmed ASCO’s Survey on COVID-19 in Oncology Registry (ASCO Registry) is an acceptable clinical trial registry for the attestation of the high-weighted practice Improvement Activity (IA), “COVID-19 Clinical Trials related to the Emergency Response & Preparedness,” under the Merit-based Incentive Payment System (MIPS).

The ASCO Registry was recently established to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient outcomes. Participating practices securely enter baseline and follow-up data on their practice and patients with cancer who are diagnosed with COVID-19. ASCO will then deliver periodic reports on key learnings, such as characteristics of patients with cancer most impacted by COVID-19, estimates of disease severity, treatment modifications or delays, implementation of telemedicine in the cancer treatment setting, and clinical outcomes among patients related to both COVID-19 and cancer.

CMS’ validation criteria for this IA states that the MIPS eligible clinician or group must provide evidence of submission of clinical data to the clinical data repository or registry supporting the COVID-19 clinical trial (i.e. screenshot from the participating clinical data repository or clinical data registry). As with all IAs, documentation requirements should remain available for at least 6 years and are expected as supporting the performance of the IA in the event the eligible clinician/group was asked by CMS to provide further information/validation of their performance.

Learn more and enroll in the ASCO Registry. MIPS updates are available on ASCO in Action.